Fig. 7.

Nobiletin decreases plasma lipids, enhances energy expenditure, improves glucose and insulin tolerance, and decreases hepatic steatosis in both HFHCdiet-fed iβ1β2AKO and WT mice. WT and iβ1β2AKO mice were fed a HFHC diet (HF) alone or a HFHC diet plus nobiletin (+Nob) for 12 weeks, n = 8–9 per group. A: ANCOVA adjusted mean energy expenditure (kilocalories per hour) over 24 h. B: RER over 24 h. C: Mean ambulatory activity (breaks per hour) over 24 h. D: Plasma TG concentrations. E: Plasma cholesterol concentrations. F: Plasma cholesterol FPLC tracing. G: Plasma LDL-C AUC calculations. H: Plasma HDL-C AUC calculations. I: Blood glucose concentrations. J: iGTT. K: AUC for iGTT. L: Plasma insulin concentrations. M: ITT, as percent of baseline glucose. N: AUC for ITT. O: Hepatic TG concentrations. P: Hepatic FC and CE concentrations. Data represent the mean ± SEM. Different letters indicate statistical differences by ANOVA with post hoc Tukey’s test (P < 0.05). N.S., no significant difference.